Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
onvatilimab (CI-8993)
i
Other names:
CI-8993, JNJ-61610588, JNJ 61610588
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Curis, ImmuNext
Drug class:
VISTA antagonist
Related drugs:
‹
CA-170 (0)
HMBD-002 (0)
KVA12123 (0)
PMC-309 (0)
SNS-101 (0)
CA-170 (0)
HMBD-002 (0)
KVA12123 (0)
PMC-309 (0)
SNS-101 (0)
›
Associations
News
Trials
Filter by
Latest
7ms
CI-8993-101: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=26, Completed, Curis, Inc. | Active, not recruiting --> Completed
7 months ago
Trial completion • Metastases
|
onvatilimab (CI-8993)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login